1
|
Niedermaier B, Kou Y, Tong E, Eichinger M, Klotz LV, Eichhorn ME, Muley T, Herth F, Kauczor HU, Peter Heußel C, Winter H. CT-guided needle biopsy is not associated with increased ipsilateral pleural metastasis. Lung Cancer 2024; 194:107890. [PMID: 39003936 DOI: 10.1016/j.lungcan.2024.107890] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2024] [Revised: 05/24/2024] [Accepted: 07/09/2024] [Indexed: 07/16/2024]
Abstract
INTRODUCTION Histological confirmation of a lung tumor is the prerequisite for treatment planning. It has been suspected that CT-guided needle biopsy (CTGNB) exposes the patient to a higher risk of pleural recurrence. However, the distance between tumor and pleura has largely been neglected as a possible confounder when comparing CTGNB to bronchoscopy. METHODS All patients with lung cancer histologically confirmed by bronchoscopy or CTGNB between 2010 and 2020 were enrolled and studied. Patients' medical histories, radiologic and pathologic findings and surgical records were reviewed. Pleural recurrence was diagnosed by pleural biopsy, fluid cytology, or by CT chest imaging showing progressive pleural nodules. RESULTS In this retrospective unicenter analysis, 844 patients underwent curative resection for early-stage lung cancer between 2010 and 2020. Median follow-up was 47.5 months (3-137). 27 patients (3.2 %) with ipsilateral pleural recurrence (IPR) were identified. The distance of the tumor to the pleura was significantly smaller in patients who underwent CTGNB. A tendency of increased risk of IPR was observed in tumors located in the lower lobe (HR: 2.18 [±0.43], p = 0.068), but only microscopic pleural invasion was a significant independent predictive factor for increased risk of IPR (HR: 5.33 [± 0.51], p = 0.001) by multivariate cox analysis. Biopsy by CTGNB did not affect IPR (HR: 1.298 [± 0.39], p = 0.504). CONCLUSION CTGNB is safe and not associated with an increased incidence of IPR in our cohort of patients. This observation remains to be validated in a larger multicenter patient cohort.
Collapse
Affiliation(s)
- Benedikt Niedermaier
- Department of Thoracic Surgery, Thoraxklinik at the University of Heidelberg, Heidelberg, Germany; Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research, Heidelberg, Germany.
| | - Yao Kou
- Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research, Heidelberg, Germany; Department of Diagnostic and Interventional Radiology, University Hospital Heidelberg, Heidelberg, Germany
| | - Elizabeth Tong
- Department of Diagnostic and Interventional Radiology, Thoraxklinik at the Heidelberg University Hospital, Heidelberg, Germany; Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research, Heidelberg, Germany; Department of Diagnostic and Interventional Radiology, University Hospital Heidelberg, Heidelberg, Germany
| | - Monika Eichinger
- Department of Diagnostic and Interventional Radiology, Thoraxklinik at the Heidelberg University Hospital, Heidelberg, Germany; Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research, Heidelberg, Germany; Department of Diagnostic and Interventional Radiology, University Hospital Heidelberg, Heidelberg, Germany
| | - Laura V Klotz
- Department of Thoracic Surgery, Thoraxklinik at the University of Heidelberg, Heidelberg, Germany; Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research, Heidelberg, Germany
| | - Martin E Eichhorn
- Department of Thoracic Surgery, Thoraxklinik at the University of Heidelberg, Heidelberg, Germany; Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research, Heidelberg, Germany
| | - Thomas Muley
- Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research, Heidelberg, Germany; Translational Research Unit, Thoraxklinik at University Hospital Heidelberg, Heidelberg, Germany
| | - Felix Herth
- Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research, Heidelberg, Germany; Department of Pneumology and Critical Care Medicine, Thoraxklinik at the University of Heidelberg, Heidelberg, Germany
| | - Hans-Ulrich Kauczor
- Department of Diagnostic and Interventional Radiology, Thoraxklinik at the Heidelberg University Hospital, Heidelberg, Germany; Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research, Heidelberg, Germany; Department of Diagnostic and Interventional Radiology, University Hospital Heidelberg, Heidelberg, Germany
| | - Claus Peter Heußel
- Department of Diagnostic and Interventional Radiology, Thoraxklinik at the Heidelberg University Hospital, Heidelberg, Germany; Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research, Heidelberg, Germany; Department of Diagnostic and Interventional Radiology, University Hospital Heidelberg, Heidelberg, Germany
| | - Hauke Winter
- Department of Thoracic Surgery, Thoraxklinik at the University of Heidelberg, Heidelberg, Germany; Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research, Heidelberg, Germany
| |
Collapse
|
2
|
Araujo-Filho JAB, Chang J, Mayoral M, Plodkowski AJ, Perez-Johnston R, Lobaugh S, Zheng J, Rusch VW, Rekhtman N, Ginsberg MS. Are there imaging characteristics that can distinguish separate primary lung carcinomas from intrapulmonary metastases using next-generation sequencing as a gold standard? Lung Cancer 2021; 153:158-164. [PMID: 33529990 DOI: 10.1016/j.lungcan.2021.01.019] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2020] [Revised: 12/25/2020] [Accepted: 01/16/2021] [Indexed: 01/15/2023]
Abstract
OBJECTIVES Distinguishing separate primary lung carcinomas (SPLCs) from intrapulmonary metastases (IPMs) in non-small cell lung cancer (NSCLC) patients is a challenging dilemma in clinical practice. Next-generation sequencing (NGS) was recently shown to represent a robust molecular method for clonal discrimination in this setting. In this study, using clonal relationships established by comprehensive NGS as the ground truth, we investigated whether NSCLC patients with SPLCs versus IPMs exhibit distinct imaging characteristics. MATERIAL AND METHODS This retrospective study included patients who underwent pre-treatment computed tomography (CT) and/or positron emission tomography/CT (PET/CT) imaging followed by surgical resection for >1 NSCLC. Nodular, parenchymal, pleural, and ancillary CT features, as well as maximum standardized uptake values (SUVs) on PET/CT were recorded. Rao-Scott chi-square, Wilcoxon rank-sum, and Fisher's exact tests were used in patient- and lesion-level comparisons. RESULTS This study included 60 patients (median age = 69 years, 68 % female) with 127 individual tumors comprising 51 SPLC vs 23 IPM tumor pairs based on NGS profiling. SPLCs were associated with subsolid consistency (P = 0.005) and spiculated contours (P < 0.001), while IPMs were associated with greater difference of size between lesions (P = 0.017) or pure solid consistency of the smaller lesion (P = 0.011). Lymph node involvement was more frequent in IPMs than SPLCs (P = 0.036). SUV measurements were not useful for differentiation (P > 0.05). CONCLUSION Selected preoperative CT features are distributed differentially in SPLCs and IPMs, suggesting that imaging may have a role in distinguishing clonal relationships of tumors in patients with >1 NSCLC.
Collapse
Affiliation(s)
- Jose Arimateia Batista Araujo-Filho
- Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA; Department of Radiology, Hospital Sirio-Libanes, Rua Adma Jafet, 91, Sao Paulo, SP, 01308-050, Brazil.
| | - Jason Chang
- Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA
| | - Maria Mayoral
- Diagnostic Imaging Center, Hospital Clínic of Barcelona, University of Barcelona, Villarroel 170, Barcelona, Catalonia, 08036, Spain
| | - Andrew J Plodkowski
- Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA
| | - Rocio Perez-Johnston
- Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA
| | - Stephanie Lobaugh
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA
| | - Junting Zheng
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA
| | - Valerie W Rusch
- Thoracic Surgery Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA
| | - Natasha Rekhtman
- Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA
| | - Michelle S Ginsberg
- Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA
| |
Collapse
|
3
|
Song Y, Jia Z, Wu P, Wang W, Ou Q, Bao H, Yu M, Wu X, Liu P, Liang N, Zhang S, Li S. Comprehensive genomic profiling aids in understanding the lesion origins of a patient with six synchronous invasive lung adenocarcinomas: a case study. BMC Pulm Med 2020; 20:80. [PMID: 32245453 PMCID: PMC7118875 DOI: 10.1186/s12890-020-1119-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2019] [Accepted: 03/19/2020] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Synchronous multiple primary lung cancers (sMPLC) are rare forms of lung cancer, and their diagnosis remains as a significant challenge. Distinguishing sMPLC from advanced disease is important as their prognoses and therapeutic management vary dramatically. CASE PRESENTATION The patient was a 56-year-old Chinese male who exhibited six synchronous invasive adenocarcinomas at diagnosis [T2(6)N0M0], and who achieved durable clinical benefit under adjuvant chemotherapy for 41 months following wedge resection and lobectomy. Whole-exome sequencing revealed that two lesions (L4 and L6) in the left upper lobe of the patient's lung shared 28 nonsynonymous mutations; thus, suggesting that the lesions may have arisen from a common ancestor at the early stages of tumorigenesis, and spread into distinct histologic subtypes. Moreover, while L5 was in the same lobe as L4 and L6, it represented a distinct lineage as it did not share any mutations with other lesions. Notably, the BRAF V600E oncogenic mutation was exclusive to L5. In addition, the KRAS G12C mutation was identified in three lesions (L1-L3) located in the right lung, which may have resulted from convergent evolution. CONCLUSION We report a patient with six synchronous invasive adenocarcinomas who demonstrated durable clinical benefits under adjuvant chemotherapy following surgical treatment. While cancer staging is one of the many challenges associated with sMPLC, the data generated through next-generation sequencing can provide information on lesion origins, and thus, advance the era of precision medicine.
Collapse
Affiliation(s)
- Yang Song
- Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, China
| | - Ziqi Jia
- Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, China.,Peking Union Medical College, Eight-Year MD Program, Chinese Academy of Medical Sciences, Beijing, 100730, China
| | - Pancheng Wu
- Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, China.,Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, China
| | - Weiwei Wang
- Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, China
| | - Qiuxiang Ou
- Translational Medicine Research Institute, Geneseeq Technology Inc., Toronto, Canada
| | - Hua Bao
- Translational Medicine Research Institute, Geneseeq Technology Inc., Toronto, Canada
| | - Man Yu
- Translational Medicine Research Institute, Geneseeq Technology Inc., Toronto, Canada
| | - Xue Wu
- Translational Medicine Research Institute, Geneseeq Technology Inc., Toronto, Canada
| | - Peng Liu
- Medical Research Center, Central Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, China
| | - Naixin Liang
- Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, China.
| | - Shuyang Zhang
- Medical Research Center, Central Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, China.,Department of Cardiology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China
| | - Shanqing Li
- Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, China
| |
Collapse
|
4
|
Murphy SJ, Harris FR, Kosari F, Barreto Siqueira Parrilha Terra S, Nasir A, Johnson SH, Serla V, Smadbeck JB, Halling GC, Karagouga G, Sukov WR, Leventakos K, Yang P, Peikert T, Mansfield AS, Wigle DA, Yi ES, Kipp BR, Vasmatzis G, Aubry MC. Using Genomics to Differentiate Multiple Primaries From Metastatic Lung Cancer. J Thorac Oncol 2019; 14:1567-1582. [PMID: 31103780 DOI: 10.1016/j.jtho.2019.05.008] [Citation(s) in RCA: 50] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2018] [Revised: 04/01/2019] [Accepted: 05/06/2019] [Indexed: 12/11/2022]
Abstract
INTRODUCTION Genomic technologies present a promising mechanism of resolving the clinical dilemma of distinguishing independent primary tumors from intrapulmonary metastases in NSCLC. We evaluated the utility of discordant mapping somatic junctions from chromosomal rearrangements in diagnosing metastatic disease compared to the current standard histologic review. MATERIAL AND METHODS Mate-pair sequencing was performed on DNA extracted from 76 distinct tumors from 37 cases of multiple lung cancers. Discordant mapping junctions and chromosomal copy levels were assessed for each tumor. Blood-derived DNA was available on 22 of these cases for germline assessments. A lung cancer next-generation sequencing panel was additionally performed on tumor pairs from 17 patients. RESULTS Whereas mate-pair sequencing was able to classify lineage in all tumor pairs, histologic review appeared to misclassify lineage in 9 of 33 (27%) same-histology tumor pair comparisons. Based on disagreement between the reviewing pathologists, histopathologic lineage was classified as indeterminate in seven cases. In two cases where pathologists agreed on a metastatic call, no shared junctions were found suggesting independent primaries. Although germline junctions passing algorithmic filters were common, on average less than three were present and all had predictable structures of small focal rearrangements or transposons. Evaluation of shared chromosomal copy changes and driver mutations through a lung cancer next-generation sequencing panel, while informative, were nondefinitive in calling lineage in all cases. CONCLUSIONS The highly unique nature and prevalence of chromosomal rearrangement in lung cancers provide a useful and definitive technique for calling lineage in multifocal lung cancer.
Collapse
Affiliation(s)
- Stephen J Murphy
- Center for Individualized Medicine, Biomarker Discovery Program, Mayo Clinic, Rochester, Minnesota
| | - Faye R Harris
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota
| | - Farhad Kosari
- Center for Individualized Medicine, Biomarker Discovery Program, Mayo Clinic, Rochester, Minnesota
| | - Simone Barreto Siqueira Parrilha Terra
- Center for Individualized Medicine, Biomarker Discovery Program, Mayo Clinic, Rochester, Minnesota; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota
| | - Aqsa Nasir
- Center for Individualized Medicine, Biomarker Discovery Program, Mayo Clinic, Rochester, Minnesota
| | - Sarah H Johnson
- Center for Individualized Medicine, Biomarker Discovery Program, Mayo Clinic, Rochester, Minnesota
| | - Vishnu Serla
- Center for Individualized Medicine, Biomarker Discovery Program, Mayo Clinic, Rochester, Minnesota; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota
| | - James B Smadbeck
- Center for Individualized Medicine, Biomarker Discovery Program, Mayo Clinic, Rochester, Minnesota
| | - Geoffrey C Halling
- Center for Individualized Medicine, Biomarker Discovery Program, Mayo Clinic, Rochester, Minnesota
| | - Giannoula Karagouga
- Center for Individualized Medicine, Biomarker Discovery Program, Mayo Clinic, Rochester, Minnesota
| | - William R Sukov
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota
| | | | - Ping Yang
- Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota
| | - Tobias Peikert
- Department of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota
| | | | - Dennis A Wigle
- Department of General Thoracic Surgery, Mayo Clinic, Rochester, Minnesota
| | - Eunhee S Yi
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota
| | - Benjamin R Kipp
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota
| | - George Vasmatzis
- Center for Individualized Medicine, Biomarker Discovery Program, Mayo Clinic, Rochester, Minnesota
| | | |
Collapse
|
5
|
Radonic T, Dickhoff C, Mino-Kenudson M, Lely R, Paul R, Thunnissen E. Gross handling of pulmonary resection specimen: maintaining the 3-dimensional orientation. J Thorac Dis 2019; 11:S37-S44. [PMID: 30775026 PMCID: PMC6353737 DOI: 10.21037/jtd.2018.12.36] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2018] [Accepted: 12/06/2018] [Indexed: 01/10/2023]
Abstract
There is limited literature on the gross handling of lung resection specimens. Microscopic examination of the specimen, TNM staging and predictive biomarker testing are fully dependent on an adequate gross handling. In this paper, we present a 3-dimensional (3D) grossing method of oncological lung resection specimens, which ensures proper fixation of the tumor tissue, but also enables accurate correlation with the pre-surgical imaging.
Collapse
Affiliation(s)
- Teodora Radonic
- Department of Pathology Amsterdam University Medical Centers, VU University Medical Center, De Boelelaan 1117, Amsterdam, The Netherlands
| | - Chris Dickhoff
- Department of Surgery, Amsterdam University Medical Centers, VU University Medical Center, De Boelelaan 1117, Amsterdam, The Netherlands
- Department of Cardiothoracic Surgery, Amsterdam University Medical Centers, VU University Medical Center, De Boelelaan 1117, Amsterdam, The Netherlands
| | - Mari Mino-Kenudson
- Department of Pathology, Massachusetts General Hospital, Boston, MA, USA
| | - Rutger Lely
- Department of Radiology, Amsterdam University Medical Centers, VU University Medical Center, De Boelelaan 1117, Amsterdam, The Netherlands
| | - Rick Paul
- Department of Cardiothoracic Surgery, Amsterdam University Medical Centers, VU University Medical Center, De Boelelaan 1117, Amsterdam, The Netherlands
| | - Erik Thunnissen
- Department of Pathology Amsterdam University Medical Centers, VU University Medical Center, De Boelelaan 1117, Amsterdam, The Netherlands
| |
Collapse
|
6
|
The IASLC Lung Cancer Staging Project: Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2016; 11:651-665. [DOI: 10.1016/j.jtho.2016.01.025] [Citation(s) in RCA: 163] [Impact Index Per Article: 20.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2015] [Revised: 01/20/2016] [Accepted: 01/21/2016] [Indexed: 12/22/2022]
|
7
|
Zhang Y, Hu H, Wang R, Ye T, Pan Y, Wang L, Zhang Y, Li H, Li Y, Shen L, Yu Y, Sun Y, Chen H, Garfield D. Synchronous Non-small Cell Lung Cancers: Diagnostic Yield can be Improved by Histologic and Genetic Methods. Ann Surg Oncol 2014; 21:4369-74. [DOI: 10.1245/s10434-014-3840-1] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2014] [Indexed: 12/11/2022]
|
8
|
|
9
|
Abstract
The TNM staging system is the most important prognostic factor for lung cancer. The most encountered difficulties in pathologic staging of lung cancer include assessment of pleural invasion, synchronous tumor nodules, and lymph node sampling.
Collapse
Affiliation(s)
- Sanja Dacic
- From the Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
| |
Collapse
|
10
|
|
11
|
Shah AA, Barfield ME, Kelsey CR, Onaitis MW, Tong B, Harpole D, D'Amico TA, Berry MF. Outcomes After Surgical Management of Synchronous Bilateral Primary Lung Cancers. Ann Thorac Surg 2012; 93:1055-60; discussion 1060. [DOI: 10.1016/j.athoracsur.2011.12.070] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/27/2011] [Revised: 12/23/2011] [Accepted: 12/30/2011] [Indexed: 10/28/2022]
|
12
|
Abstract
Carcinoma in children differs from that occurring in adults. It is far rarer and represents only a small fraction of all pediatric cancer diagnoses. Pediatric sarcomas were among the first tumors in which recurrent chromosomal aberrations were discovered. Once defined, these recurrent aberrations, many of them translocations, became incorporated into the pathologist's diagnostic armamentarium. In the past several years, defining chromosomal rearrangements have been identified in pediatric carcinomas as well, and this has become a new frontier in pathologic diagnosis. This article provides an overview of pediatric carcinoma as well as a detailed review of selected types of carcinoma that in particular can present diagnostic difficulty to the practicing pathologist and illustrate new and emerging concepts in pediatric carcinoma.
Collapse
Affiliation(s)
- Sara O Vargas
- Department of Pathology, Children's Hospital and Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115, USA.
| |
Collapse
|
13
|
Abstract
The tumor-node-metastasis (TNM) system is the most commonly used staging system for cancers, including lung cancer. The TNM descriptors and the stage groupings reflect differences in patient prognosis and choices for specific therapies. Generally, the higher the T, N, or M, and the higher the stage grouping, the worse the prognosis is for patients in that category. TNM stage is traditionally the most important factor predicting survival of lung cancer patients.
Collapse
Affiliation(s)
- Philip T Cagle
- Department of Pathology and Laboratory Medicine, Weil Medical College of Cornell University, 1300 York Avenue, New York, NY 10065, USA; Department of Pathology, The Methodist Hospital, Main Building, Room 227B, 6565 Fannin Street, Houston, TX 77030, USA.
| |
Collapse
|
14
|
Predictors of Outcomes after Surgical Treatment of Synchronous Primary Lung Cancers. J Thorac Oncol 2010; 5:197-205. [DOI: 10.1097/jto.0b013e3181c814c5] [Citation(s) in RCA: 93] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
15
|
Butnor KJ, Beasley MB, Cagle PT, Grunberg SM, Kong FM, Marchevsky A, Okby NT, Roggli VL, Suster S, Tazelaar HD, Travis WD. Protocol for the Examination of Specimens From Patients With Primary Non–Small Cell Carcinoma, Small Cell Carcinoma, or Carcinoid Tumor of the Lung. Arch Pathol Lab Med 2009; 133:1552-9. [DOI: 10.5858/133.10.1552] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/02/2009] [Indexed: 11/06/2022]
Affiliation(s)
- Kelly J. Butnor
- From the Departments of Pathology and Laboratory Medicine (Dr Butnor) and Hematology/Oncology (Dr Grunberg), Fletcher Allen Health Care, University of Vermont, Burlington; the Department of Pathology, Mount Sinai Medical Center, New York, New York (Dr Beasley); the Department of Pathology, The Methodist Hospital, Houston, Texas (Dr Cagle); the Department of Radiation Oncology, Veterans Administra
| | - Mary Beth Beasley
- From the Departments of Pathology and Laboratory Medicine (Dr Butnor) and Hematology/Oncology (Dr Grunberg), Fletcher Allen Health Care, University of Vermont, Burlington; the Department of Pathology, Mount Sinai Medical Center, New York, New York (Dr Beasley); the Department of Pathology, The Methodist Hospital, Houston, Texas (Dr Cagle); the Department of Radiation Oncology, Veterans Administra
| | - Philip T. Cagle
- From the Departments of Pathology and Laboratory Medicine (Dr Butnor) and Hematology/Oncology (Dr Grunberg), Fletcher Allen Health Care, University of Vermont, Burlington; the Department of Pathology, Mount Sinai Medical Center, New York, New York (Dr Beasley); the Department of Pathology, The Methodist Hospital, Houston, Texas (Dr Cagle); the Department of Radiation Oncology, Veterans Administra
| | - Steven M. Grunberg
- From the Departments of Pathology and Laboratory Medicine (Dr Butnor) and Hematology/Oncology (Dr Grunberg), Fletcher Allen Health Care, University of Vermont, Burlington; the Department of Pathology, Mount Sinai Medical Center, New York, New York (Dr Beasley); the Department of Pathology, The Methodist Hospital, Houston, Texas (Dr Cagle); the Department of Radiation Oncology, Veterans Administra
| | - Feng-Ming Kong
- From the Departments of Pathology and Laboratory Medicine (Dr Butnor) and Hematology/Oncology (Dr Grunberg), Fletcher Allen Health Care, University of Vermont, Burlington; the Department of Pathology, Mount Sinai Medical Center, New York, New York (Dr Beasley); the Department of Pathology, The Methodist Hospital, Houston, Texas (Dr Cagle); the Department of Radiation Oncology, Veterans Administra
| | - Alberto Marchevsky
- From the Departments of Pathology and Laboratory Medicine (Dr Butnor) and Hematology/Oncology (Dr Grunberg), Fletcher Allen Health Care, University of Vermont, Burlington; the Department of Pathology, Mount Sinai Medical Center, New York, New York (Dr Beasley); the Department of Pathology, The Methodist Hospital, Houston, Texas (Dr Cagle); the Department of Radiation Oncology, Veterans Administra
| | - Nader T. Okby
- From the Departments of Pathology and Laboratory Medicine (Dr Butnor) and Hematology/Oncology (Dr Grunberg), Fletcher Allen Health Care, University of Vermont, Burlington; the Department of Pathology, Mount Sinai Medical Center, New York, New York (Dr Beasley); the Department of Pathology, The Methodist Hospital, Houston, Texas (Dr Cagle); the Department of Radiation Oncology, Veterans Administra
| | - Victor L. Roggli
- From the Departments of Pathology and Laboratory Medicine (Dr Butnor) and Hematology/Oncology (Dr Grunberg), Fletcher Allen Health Care, University of Vermont, Burlington; the Department of Pathology, Mount Sinai Medical Center, New York, New York (Dr Beasley); the Department of Pathology, The Methodist Hospital, Houston, Texas (Dr Cagle); the Department of Radiation Oncology, Veterans Administra
| | - Saul Suster
- From the Departments of Pathology and Laboratory Medicine (Dr Butnor) and Hematology/Oncology (Dr Grunberg), Fletcher Allen Health Care, University of Vermont, Burlington; the Department of Pathology, Mount Sinai Medical Center, New York, New York (Dr Beasley); the Department of Pathology, The Methodist Hospital, Houston, Texas (Dr Cagle); the Department of Radiation Oncology, Veterans Administra
| | - Henry D. Tazelaar
- From the Departments of Pathology and Laboratory Medicine (Dr Butnor) and Hematology/Oncology (Dr Grunberg), Fletcher Allen Health Care, University of Vermont, Burlington; the Department of Pathology, Mount Sinai Medical Center, New York, New York (Dr Beasley); the Department of Pathology, The Methodist Hospital, Houston, Texas (Dr Cagle); the Department of Radiation Oncology, Veterans Administra
| | - William D. Travis
- From the Departments of Pathology and Laboratory Medicine (Dr Butnor) and Hematology/Oncology (Dr Grunberg), Fletcher Allen Health Care, University of Vermont, Burlington; the Department of Pathology, Mount Sinai Medical Center, New York, New York (Dr Beasley); the Department of Pathology, The Methodist Hospital, Houston, Texas (Dr Cagle); the Department of Radiation Oncology, Veterans Administra
| |
Collapse
|
16
|
Westphal FL, Lima LCD, Andrade EO, Lima Netto JC, Silva ASD, Carvalho BCN. Characteristics of patients with lung cancer in the city of Manaus, Brazil. J Bras Pneumol 2009; 35:157-63. [PMID: 19287919 DOI: 10.1590/s1806-37132009000200009] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2008] [Accepted: 08/08/2008] [Indexed: 11/21/2022] Open
Abstract
OBJECTIVE To analyze the characteristics of patients with lung cancer. METHODS A retrospective descriptive study of patients receiving a histopathological diagnosis of lung cancer between 1995 and 2002 in the city of Manaus, Brazil. Data were collected from the medical archives of three hospitals. Statistical analyses were carried out, and survival curves were generated by means of an actuarial estimator. RESULTS Of the 352 patients selected, 262 (74.4%) were male and 90 (25.6%) were female. The mean age was 62 years. The following histological types were identified: squamous cell carcinoma, 62.8%; adenocarcinoma, 24.7%; small cell carcinoma, 9.1%; and large cell carcinoma, 3.4%. The most common stages were stages IIIB and IV, in 45% and 21.5%, respectively. Of the total sample, 73.4% were submitted to treatment. Of these, 51.4% underwent radiotherapy; 16.6%, surgery; 15.8%, chemotherapy; and 16.2%, radiotherapy in association with chemotherapy. Cumulative survival rates were low: three-year survival was 6.5%, and five-year survival was 3.5%. CONCLUSIONS In this group of patients with lung cancer, survival rates were considerably lower than those reported in the literature. This might be attributable to the limited access to the specialized health care system and the advanced stage of the disease at diagnosis.
Collapse
Affiliation(s)
- Fernando Luiz Westphal
- Hospital Universitário Getúlio Vargas, Universidade Federal do Amazonas, Manaus, AM, Brasil.
| | | | | | | | | | | |
Collapse
|
17
|
Hiroshima K, Yusa T, Kameya T, Ito I, Kaneko K, Kadoyama C, Kishi H, Saitoh Y, Ozaki D, Itami M, Iwata T, Iyoda A, Kawai T, Yoshino I, Nakatani Y. Malignant pleural mesothelioma: Clinicopathology of 16 extrapleural pneumonectomy patients with special reference to early stage features. Pathol Int 2009; 59:537-45. [DOI: 10.1111/j.1440-1827.2009.02404.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
18
|
Visceral Pleura Invasion Impact on Non-small Cell Lung Cancer Patient Survival: Its Implications for the Forthcoming TNM Staging Based on a Large-Scale Nation-Wide Database. J Thorac Oncol 2009; 4:959-63. [DOI: 10.1097/jto.0b013e3181a85d5e] [Citation(s) in RCA: 84] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
19
|
Shim HS, Park IK, Lee CY, Chung KY. Prognostic significance of visceral pleural invasion in the forthcoming (seventh) edition of TNM classification for lung cancer. Lung Cancer 2009; 65:161-5. [PMID: 19128855 DOI: 10.1016/j.lungcan.2008.11.008] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2008] [Revised: 10/08/2008] [Accepted: 11/04/2008] [Indexed: 11/29/2022]
Affiliation(s)
- Hyo Sup Shim
- Department of Pathology, Yonsei University College of Medicine, 134 Shinchon-dong, Seodaemun-gu, Seoul 120-752, Republic of Korea.
| | | | | | | |
Collapse
|
20
|
Visceral Pleural Invasion: Pathologic Criteria and Use of Elastic Stains: Proposal for the 7th Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2008; 3:1384-90. [DOI: 10.1097/jto.0b013e31818e0d9f] [Citation(s) in RCA: 209] [Impact Index Per Article: 13.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|